Clinical Trial Search

Primary: Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population — 14.1; 15.4; 29.5; 16.4 Percentage…

Primary: Change From Baseline in Sitting Clinic Diastolic Blood Pressure. — -10.8; -13.1; -11.5; -13.6 mmHg — p=0.0631

Primary: The Percentage of Participants With of Hypercalcemia — 40.74; 63.33; 60.87; 65.38 Percentage of participants

Primary: Percent Change in Inflammatory Acne Lesion Counts From Baseline to Week 12 — -37.4; -34.7; -30.7; -44.8 Percent change

Primary: Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco — 7; 8; 6 participants — p=0.52

Primary: Levels of Growth Hormone Post Exercise — 4.95; 1.41 ng/ml — p=<0.02

Primary: Number of Participants With Tumor Response (Stable Disease) — 5 participants

Primary: The Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by Treatment — 1.77; 1.77; 1.80; 1.71…

Primary: Number of Participants With Response — 2; 2; 4; 6 participants

Primary: Number of Participants With Response — 0; 0; 4; 5 Participants

Primary: Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study — 47.8; 71.1; 62.5 Percentage of participants

Primary: Percent Predicted FEV1 AUC0-4 Response at the End of Week 12 — -1.74; 1.20; 1.65 Percentage change — p=0.001

Primary: Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs) — 0; 0 Participants

Primary: Number of Participants Reporting Solicited Subjective Local Reactions After the First Vaccination — 60; 69; 102; 98 Participants

Primary: Monthly Rates of Anti-VEGF (Vascular Endothelial Growth Factor) Injections — 0.42; 0.83; 0.34; 0.83 Injections per Month